Founded in 1787, the University of Pittsburgh has built a rich legacy of neuroscience innovation. Today, Pitt ranks #6 in NIH funding, #2 in National Institute of Mental Health funding, and #14 in NINDS funding among educational institutions. With $1.2B in overall research expenditures, dedicated research centers, and award-winning faculty, Pitt drives breakthrough discoveries in Alzheimer's disease, Parkinson's disease, stroke, ALS, and beyond.
Research Area: Alzheimer's Disease | Diagnostics
Description: Researchers have identified blood biomarkers that can predict whether cognitively healthy elderly individuals will develop Alzheimer's disease, potentially unlocking new approaches to early intervention and disease monitoring. This work offers critical insights into Alzheimer's disease progression and opens pathways for diagnostic development.
Ideal Partner Profile: Diagnostic companies, pharmaceutical partners developing Alzheimer's therapies seeking companion diagnostics, and companies focused on preventive neurology.
Research Area: Stroke | Neuromodulation | Medical Devices
Description: Clinical trials have demonstrated that stimulator implant technology can restore movement in stroke patients, representing a significant advancement in post-stroke rehabilitation. This breakthrough offers new hope for patients with mobility impairments and creates opportunities for therapeutic device development.
Ideal Partner Profile: Medical device companies, neuromodulation technology developers, and rehabilitation technology partners.
Research Area: ALS | Neurodegeneration | Drug Development
Description: Scientists are unraveling the molecular pathogenesis of ALS through research on RNA binding proteins, phase transitions, and biomolecular condensates. This work has already led to the formation of Confluence Therapeutics, a company focused on developing new ALS treatments, demonstrating clear translational potential.
Ideal Partner Profile: Biotech and pharmaceutical companies developing neurodegeneration therapies, particularly those targeting RNA metabolism and protein aggregation.
Research Area: Alzheimer's Disease | Research Tools | Drug Discovery
Description: Researchers have developed OptoTAU, a novel light-responsive tau protein and optogenetic model of tau aggregation, alongside advanced tools integrating mouse genetics, electrophysiology, and behavioral studies. These innovations enable more precise investigation of Alzheimer's mechanisms and therapeutic targets.
Ideal Partner Profile: Pharmaceutical companies developing Alzheimer's therapies, CROs seeking advanced research models, and research tool companies.
